Enhancing the sensitivity of pharmacophore-based virtual screening by incorporating customized ZBG features: A case study using histone deacetylase 8

Journal of Chemical Information and Modeling

Volumn 55, Issue 4, 2015, Pages 861-871

  Hou, Xuben ^a   Du, Jintong ^b   Liu, Renshuai ^a   Zhou, Yi ^a   Li, Minyong ^a   Xu, Wenfang ^a   Fang, Hao ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; DISEASES; MOLECULAR DYNAMICS;

ANTI-PROLIFERATION ACTIVITIES; EPIGENETIC REGULATION; HDAC INHIBITORS; HIGH SPECIFICITY; HISTONE DEACETYLASES; MOLECULAR DOCKING; PHARMACOPHORE MODELING; VIRTUAL SCREENING;

PHARMACODYNAMICS;

HDAC8 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; REPRESSOR PROTEIN; ZINC;

ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; COMPUTER INTERFACE; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; PROCEDURES; PROTEIN CONFORMATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; PROTEIN CONFORMATION; REPRESSOR PROTEINS; USER-COMPUTER INTERFACE; ZINC;

EID: 84928652393     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci500762z     Document Type: Article

References (87)

1. Rodriguez-Paredes, M.; Esteller, M. Cancer epigenetics reaches mainstream oncology Nat. Med. 2011, 17, 330-9
2. Arrowsmith, C. H.; Bountra, C.; Fish, P. V.; Lee, K.; Schapira, M. Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discovery 2012, 11, 384-400
3. Grunstein, M. Histone acetylation in chromatin structure and transcription Nature 1997, 389, 349-52
4. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M. L.; Rehman, M.; Walther, T. C.; Olsen, J. V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 2009, 325, 834-40
5. Glozak, M. A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins Gene 2005, 363, 15-23
6. Gui, C. Y.; Ngo, L.; Xu, W. S.; Richon, V. M.; Marks, P. A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 1241-6
7. Zhao, S.; Xu, W.; Jiang, W.; Yu, W.; Lin, Y.; Zhang, T.; Yao, J.; Zhou, L.; Zeng, Y.; Li, H.; Li, Y.; Shi, J.; An, W.; Hancock, S. M.; He, F.; Qin, L.; Chin, J.; Yang, P.; Chen, X.; Lei, Q.; Xiong, Y.; Guan, K. L. Regulation of cellular metabolism by protein lysine acetylation Science 2010, 327, 1000-4
8. Yang, X. J.; Seto, E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention Oncogene 2007, 26, 5310-8
9. Bieliauskas, A. V.; Pflum, M. K. Isoform-selective histone deacetylase inhibitors Chem. Soc. Rev. 2008, 37, 1402-13
10. Marson, C. M.; Matthews, C. J.; Yiannaki, E.; Atkinson, S. J.; Soden, P. E.; Shukla, L.; Lamadema, N.; Thomas, N. S. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit J. Med. Chem. 2013, 56, 6156-74
11. Wang, D. F.; Helquist, P.; Wiech, N. L.; Wiest, O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases J. Med. Chem. 2005, 48, 6936-47
12. Ortore, G.; Di Colo, F.; Martinelli, A. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities J. Chem. Inf. Model. 2009, 49, 2774-85
13. Wambua, M. K.; Nalawansha, D. A.; Negmeldin, A. T.; Pflum, M. K. Mutagenesis studies of the 14 A internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design J. Med. Chem. 2014, 57, 642-50
14. Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer therapy J. Clin. Oncol. 2009, 27, 5459-68
15. Garber, K. HDAC inhibitors overcome first hurdle Nat. Biotechnol. 2007, 25, 17-9
16. Zhang, L.; Han, Y.; Jiang, Q.; Wang, C.; Chen, X.; Li, X.; Xu, F.; Jiang, Y.; Wang, Q.; Xu, W. Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy Med. Res. Rev. 2015, 35, 63-84
17. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: from bench to clinic J. Med. Chem. 2008, 51, 1505-29
18. Glaser, K. B. HDAC inhibitors: clinical update and mechanism-based potential Biochem. Pharmacol. 2007, 74, 659-71
19. Kirschbaum, M. H.; Foon, K. A.; Frankel, P.; Ruel, C.; Pulone, B.; Tuscano, J. M.; Newman, E. M. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study Leuk. Lymphoma 2014, 55, 2301-4
20. Wagner, J. M.; Hackanson, B.; Lubbert, M.; Jung, M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy Clin. Epigenet. 2010, 1, 117-136
21. Lavecchia, A.; Di Giovanni, C.; Cerchia, C.; Russo, A.; Russo, G.; Novellino, E. Discovery of a novel small molecule inhibitor targeting the frataxin/ubiquitin interaction via structure-based virtual screening and bioassays J. Med. Chem. 2013, 56, 2861-73
22. Alcaro, S.; Musetti, C.; Distinto, S.; Casatti, M.; Zagotto, G.; Artese, A.; Parrotta, L.; Moraca, F.; Costa, G.; Ortuso, F.; Maccioni, E.; Sissi, C. Identification and characterization of new DNA G-quadruplex binders selected by a combination of ligand and structure-based virtual screening approaches J. Med. Chem. 2013, 56, 843-55
23. Osolodkin, D. I.; Kozlovskaya, L. I.; Dueva, E. V.; Dotsenko, V. V.; Rogova, Y. V.; Frolov, K. A.; Krivokolysko, S. G.; Romanova, E. G.; Morozov, A. S.; Karganova, G. G.; Palyulin, V. A.; Pentkovski, V. M.; Zefirov, N. S. Inhibitors of tick-borne flavivirus reproduction from structure-based virtual screening ACS Med. Chem. Lett. 2013, 4, 869-74
24. Bowers, E. M.; Yan, G.; Mukherjee, C.; Orry, A.; Wang, L.; Holbert, M. A.; Crump, N. T.; Hazzalin, C. A.; Liszczak, G.; Yuan, H.; Larocca, C.; Saldanha, S. A.; Abagyan, R.; Sun, Y.; Meyers, D. J.; Marmorstein, R.; Mahadevan, L. C.; Alani, R. M.; Cole, P. A. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor Chem. Biol. 2010, 17, 471-82
25. Hou, X.; Li, R.; Li, K.; Yu, X.; Sun, J. P.; Fang, H. Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening J. Med. Chem. 2014, 57, 9309-22
26. Xu, L.; Zhang, Y.; Zheng, L.; Qiao, C.; Li, Y.; Li, D.; Zhen, X.; Hou, T. Discovery of novel inhibitors targeting the macrophage migration inhibitory factor via structure-based virtual screening and bioassays J. Med. Chem. 2014, 57, 3737-45
27. Siddiquee, K.; Zhang, S.; Guida, W. C.; Blaskovich, M. A.; Greedy, B.; Lawrence, H. R.; Yip, M. L.; Jove, R.; McLaughlin, M. M.; Lawrence, N. J.; Sebti, S. M.; Turkson, J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 7391-6
28. Ripphausen, P.; Nisius, B.; Peltason, L.; Bajorath, J. Quo vadis, virtual screening? A comprehensive survey of prospective applications J. Med. Chem. 2010, 53, 8461-7
29. Yang, S. Y. Pharmacophore modeling and applications in drug discovery: challenges and recent advances Drug Discovery Today 2010, 15, 444-50
30. Leach, A. R.; Gillet, V. J.; Lewis, R. A.; Taylor, R. Three-dimensional pharmacophore methods in drug discovery J. Med. Chem. 2010, 53, 539-58
31. Hou, X. B.; Du, J. T.; Zhang, J.; Du, L. P.; Fang, H.; Li, M. Y. How to Improve Docking Accuracy of AutoDock4.2: A Case Study Using Different Electrostatic Potentials J. Chem. Inf. Model. 2013, 53, 188-200
32. Zhang, X.; Li, X.; Wang, R. Interpretation of the binding affinities of PTP1B inhibitors with the MM-GB/SA method and the X-score scoring function J. Chem. Inf. Model. 2009, 49, 1033-48
33. Li, G. B.; Yang, L. L.; Wang, W. J.; Li, L. L.; Yang, S. Y. ID-Score: a new empirical scoring function based on a comprehensive set of descriptors related to protein-ligand interactions J. Chem. Inf. Model. 2013, 53, 592-600
34. Tian, S.; Sun, H.; Pan, P.; Li, D.; Zhen, X.; Li, Y.; Hou, T. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility J. Chem. Inf. Model. 2014, 54, 2664-79
35. Hahnke, V.; Todoroff, N.; Rodrigues, T.; Schneider, G. Significance estimation for sequence-based chemical similarity searching (PhAST) and application to AuroraA kinase inhibitors Future Med. Chem. 2012, 4, 1897-906
36. Moffat, K.; Gillet, V. J.; Whittle, M.; Bravi, G.; Leach, A. R. A comparison of field-based similarity searching methods: CatShape, FBSS, and ROCS J. Chem. Inf. Model. 2008, 48, 719-29
37. Therese, P. J.; Manvar, D.; Kondepudi, S.; Battu, M. B.; Sriram, D.; Basu, A.; Yogeeswari, P.; Kaushik-Basu, N. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors J. Chem. Inf. Model. 2014, 54, 539-52
38. Hou, X.; Du, J.; Fang, H.; Li, M. 3D-QSAR study on a series of Bcl-2 protein inhibitors using comparative molecular field analysis Protein Pept. Lett. 2011, 18, 440-9
39. Tang, H.; Wang, X. S.; Huang, X. P.; Roth, B. L.; Butler, K. V.; Kozikowski, A. P.; Jung, M.; Tropsha, A. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation J. Chem. Inf. Model. 2009, 49, 461-76
40. Park, H.; Kim, S.; Kim, Y. E.; Lim, S. J. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups ChemMedChem 2010, 5, 591-7
41. Li, G. B.; Yang, L. L.; Yuan, Y.; Zou, J.; Cao, Y.; Yang, S. Y.; Xiang, R.; Xiang, M. Virtual screening in small molecule discovery for epigenetic targets Methods 2015, 71, 158-66
42. Kandakatla, N.; Ramakrishnan, G. Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors Adv. Bioinf. 2014, 2014, 812148
43. Santos-Martins, D.; Forli, S.; Ramos, M. J.; Olson, A. J. AutoDock4(Zn): an improved AutoDock force field for small-molecule docking to zinc metalloproteins J. Chem. Inf. Model. 2014, 54, 2371-9
44. Pottel, J.; Therrien, E.; Gleason, J. L.; Moitessier, N. Docking Ligands into Flexible and Solvated Macromolecules. 6. Development and Application to the Docking of HDACs and other Zinc Metalloenzymes Inhibitors J. Chem. Inf. Model. 2014, 54, 254-265
45. Chaskar, P.; Zoete, V.; Rohrig, U. F. Toward On-The-Fly Quantum Mechanical/Molecular Mechanical (QM/MM) Docking: Development and Benchmark of a Scoring Function J. Chem. Inf. Model. 2014, 54, 3137-52
46. Thangapandian, S.; John, S.; Sakkiah, S.; Lee, K. W. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design Eur. J. Med. Chem. 2010, 45, 4409-17
47. Chen, Y. D.; Jiang, Y. J.; Zhou, J. W.; Yu, Q. S.; You, Q. D. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling J. Mol. Graphics Modell. 2008, 26, 1160-1168
48. Chen, Y. D.; Li, F. F.; Tang, W. Q.; Zhu, C. C.; Jiang, Y. J.; Zou, J. W.; Yu, Q. S.; You, Q. D. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment Eur. J. Med. Chem. 2009, 44, 2868-2876
49. Day, J. A.; Cohen, S. M. Investigating the selectivity of metalloenzyme inhibitors J. Med. Chem. 2013, 56, 7997-8007
50. Chen, K.; Xu, L.; Wiest, O. Computational exploration of zinc binding groups for HDAC inhibition J. Org. Chem. 2013, 78, 5051-5
51. Scarpelli, R.; Di Marco, A.; Ferrigno, F.; Laufer, R.; Marcucci, I.; Muraglia, E.; Ontoria, J. M.; Rowley, M.; Serafini, S.; Steinkuhler, C.; Jones, P. Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 6078-6082
52. Ontoria, J. M.; Altamura, S.; Di Marco, A.; Ferrigno, F.; Laufer, R.; Muraglia, E.; Palumbi, M. C.; Rowley, M.; Scarpelli, R.; Schultz-Fademrecht, C.; Serafini, S.; Steinkuhler, C.; Jones, P. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy J. Med. Chem. 2009, 52, 6782-9
53. Patil, V.; Sodji, Q. H.; Kornacki, J. R.; Mrksich, M.; Oyelere, A. K. 3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition J. Med. Chem. 2013, 56, 3492-506
54. Sodji, Q. H.; Patil, V.; Kornacki, J. R.; Mrksich, M.; Oyelere, A. K. Synthesis and Structure-Activity Relationship of 3-Hydroxypyridine-2-thione-Based Histone Deacetylase Inhibitors J. Med. Chem. 2013, 56, 9969-9981
55. Ononye, S. N.; VanHeyst, M. D.; Oblak, E. Z.; Zhou, W.; Ammar, M.; Anderson, A. C.; Wright, D. L. Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors ACS Med. Chem. Lett. 2013, 4, 757-61
56. Wang, D.; Helquist, P.; Wiest, O. Zinc binding in HDAC inhibitors: a DFT study J. Org. Chem. 2007, 72, 5446-9
57. Vanommeslaeghe, K.; Loverix, S.; Geerlings, P.; Tourwe, D. DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors Bioorg. Med. Chem. 2005, 13, 6070-82
58. McCarren, P.; Hall, M. L.; Whitehead, L. The Chemical Tuning of a Weak Zinc Binding Motif for Histone Deacetylase Using Electronic Effects Chem. Biol. Drug Des. 2012, 80, 203-214
59. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkuhler, C.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 15064-9
60. Waltregny, D.; de Leval, L.; Glenisson, W.; Tran, S. L.; North, B. J.; Bellahcene, A.; Weidle, U.; Verdin, E.; Castronovo, V. Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues Am. J. Pathol. 2004, 165, 553-564
61. Estiu, G.; West, N.; Mazitschek, R.; Greenberg, E.; Bradner, J. E.; Wiest, O. On the inhibition of histone deacetylase 8 Bioorg. Med. Chem. 2010, 18, 4103-10
62. Dowling, D. P.; Gattis, S. G.; Fierke, C. A.; Christianson, D. W. Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function Biochemistry 2010, 49, 5048-56
63. Singh, R. K.; Suzuki, T.; Mandal, T.; Balsubramanian, N.; Haldar, M.; Mueller, D. J.; Strode, J. A.; Cook, G.; Mallik, S.; Srivastava, D. K. Thermodynamics of Binding of Structurally Similar Ligands to Histone Deacetylase 8 Sheds Light on Challenges in the Rational Design of Potent and Isozyme-Selective Inhibitors of the Enzyme Biochemistry 2014, 53, 7445-7458
64. Wu, R.; Lu, Z.; Cao, Z.; Zhang, Y. Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel J. Am. Chem. Soc. 2011, 133, 6110-3
65. Kunze, M. B.; Wright, D. W.; Werbeck, N. D.; Kirkpatrick, J.; Coveney, P. V.; Hansen, D. F. Loop interactions and dynamics tune the enzymatic activity of the human histone deacetylase 8 J. Am. Chem. Soc. 2013, 135, 17862-8
66. Chen, K.; Zhang, X.; Wu, Y. D.; Wiest, O. Inhibition and mechanism of HDAC8 revisited J. Am. Chem. Soc. 2014, 136, 11636-43
67. Wu, R.; Wang, S.; Zhou, N.; Cao, Z.; Zhang, Y. A proton-shuttle reaction mechanism for histone deacetylase 8 and the catalytic role of metal ions J. Am. Chem. Soc. 2010, 132, 9471-9
68. Wu, R.; Hu, P.; Wang, S.; Cao, Z.; Zhang, Y. Flexibility of Catalytic Zinc Coordination in Thermolysin and HDAC8: A Born-Oppenheimer ab initio QM/MM Molecular Dynamics Study J. Chem. Theory Comput. 2009, 6, 337
69. Mysinger, M. M.; Carchia, M.; Irwin, J. J.; Shoichet, B. K. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking J. Med. Chem. 2012, 55, 6582-94
70. Irwin, J. J.; Shoichet, B. K. ZINC - a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45, 177-82
71. Bruserud, O.; Stapnes, C.; Ersvaer, E.; Gjertsen, B. T.; Ryningen, A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell Curr. Pharm. Biotechnol. 2007, 8, 388-400
72. Erbe, D. V.; Wang, S.; Zhang, Y. L.; Harding, K.; Kung, L.; Tam, M.; Stolz, L.; Xing, Y.; Furey, S.; Qadri, A.; Klaman, L. D.; Tobin, J. F. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms Mol. Pharmacol. 2005, 67, 69-77
73. He, R.; Zeng, L. F.; He, Y.; Zhang, S.; Zhang, Z. Y. Small molecule tools for functional interrogation of protein tyrosine phosphatases FEBS J. 2013, 280, 731-50
74. Vannini, A.; Volpari, C.; Gallinari, P.; Jones, P.; Mattu, M.; Carfi, A.; De Francesco, R.; Steinkuhler, C.; Di Marco, S. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex EMBO Rep. 2007, 8, 879-84
75. Whitehead, L.; Dobler, M. R.; Radetich, B.; Zhu, Y.; Atadja, P. W.; Claiborne, T.; Grob, J. E.; McRiner, A.; Pancost, M. R.; Patnaik, A.; Shao, W.; Shultz, M.; Tichkule, R.; Tommasi, R. A.; Vash, B.; Wang, P.; Stams, T. Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors Bioorg. Med. Chem. 2011, 19, 4626-34
76. Dowling, D. P.; Gantt, S. L.; Gattis, S. G.; Fierke, C. A.; Christianson, D. W. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors Biochemistry 2008, 47, 13554-63
77. Zhang, Y.; Feng, J.; Jia, Y.; Wang, X.; Zhang, L.; Liu, C.; Fang, H.; Xu, W. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities J. Med. Chem. 2011, 54, 2823-38
78. Jain, A. N. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine J. Med. Chem. 2003, 46, 499-511
79. Spitzer, R.; Jain, A. N. Surflex-Dock: Docking benchmarks and real-world application J. Comput.-Aided Mol. Des. 2012, 26, 687-99
80. Pronk, S.; Pall, S.; Schulz, R.; Larsson, P.; Bjelkmar, P.; Apostolov, R.; Shirts, M. R.; Smith, J. C.; Kasson, P. M.; van der Spoel, D.; Hess, B.; Lindahl, E. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit Bioinformatics 2013, 29, 845-54
81. Van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A. E.; Berendsen, H. J. GROMACS: fast, flexible, and free J. Comput. Chem. 2005, 26, 1701-18
82. Lindorff-Larsen, K.; Piana, S.; Palmo, K.; Maragakis, P.; Klepeis, J. L.; Dror, R. O.; Shaw, D. E. Improved side-chain torsion potentials for the Amber ff99SB protein force field Proteins 2010, 78, 1950-8
83. Webb, B.; Sali, A. Comparative Protein Structure Modeling Using MODELLER Curr. Protoc. Bioinf. 2014, 47, 5 6 1-5 6 32
84. Cerutti, D. S.; Duke, R. E.; Darden, T. A.; Lybrand, T. P. Staggered Mesh Ewald: An extension of the Smooth Particle-Mesh Ewald method adding great versatility J. Chem. Theory Comput. 2009, 5, 2322
85. Hess, B. P-LINCS: A parallel linear constraint solver for molecular simulation J. Chem. Theory Comput. 2008, 4, 116-122
86. Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 1355-63
87. Gordon, J. C.; Myers, J. B.; Folta, T.; Shoja, V.; Heath, L. S.; Onufriev, A. H++: a server for estimating pKas and adding missing hydrogens to macromolecules Nucleic Acids Res. 2005, 33, W368-71